611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
Genes Start Mutating Soon After Life Begins, Study FindsMore Men Than Women With Parkinson's Have Caregivers'Fountain of Youth' Gene Discovered in Secluded Amish CommunityLRRK2 Variants Linked to Lower Age at Onset of Parkinson'sKnowing Too Much About Your Genes Might Be RiskyOverlapping Surgery Appears Safe in Neurosurgical ProceduresDo I Know Ewe?Daytime Wounds May Heal Faster Than Nighttime OnesHuman vs. Animal Brainpower: More Alike Than You Might ThinkResilient Brain Connections May Help Against Alzheimer'sConcerns Surround Use of Direct-to-Consumer Genetic TestingWhen It Comes to Obesity, Genes Just Partly to BlameDoes Time of Neurosurgery Matter?Smoking Alters Genetic Relationship with Parkinson'sHealth Tip: Considering Genetic TestingDiabetes Ups Risk of MACE in Acute Coronary SyndromesScientists Spot Genes Behind Skin ColorScientists Support Genome Editing to Prevent DiseaseBrain Disconnects Spotted in Parkinson's Patients With Visual HallucinationsCoffee Doesn't Help Parkinson's Motor DisordersCan Babies Help Heart Patients?Scientists Spot Marker for CTE in Living Football PlayersNerve Stimulation Pulls Patient From 15-Year Vegetative StateWhy Your Nose May Be Key to Parkinson's RiskEvolution Not Over for HumansBrain Scans Offer Clues to Why Some Teens Pile on PoundsNew Clues to Why Yawns Are ContagiousNew Hope From Old Drugs in Fight Against Parkinson'sFirst Gene Therapy Approved in U.S.Awake for Aneurysm Brain Surgery, Better Results?Does Autism Risk Reside in Cells' Energy Engines?More Evidence Contact Sports Can Affect the BrainVirtual House Calls for Speedy, Effective Parkinson's CareSeven Imaging Biomarkers Tied to Cognition in Male FightersDiabetes Drug Shows Promise Against Parkinson'sCombined MRI Might Help Predict Brain Damage in BoxersMedical Reality Catches Up to Science FictionNoninvasive Brain Test May Pinpoint Type of DementiaIn Mice, Brain Cells Discovered That Might Control AgingScans May Show Consciousness in 'Comatose' PatientsBoxers, MMA Fighters May Face Long-Term Harm to Brain: StudyFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Early Parkinson's May Prompt Vision ProblemsWhole-Genome Sequencing of Uncertain Clinical UtilityCould Shift Work Damage Your DNA?Gene Sequencing May Reveal Risks for Rare DiseasesRogue Genes May Cause Some ALS CasesSticky Brain 'Plaques' Implicated in Alzheimer's AgainEven Your Bones Can Get Fat, Mouse Study SuggestsDoes a Low-Fat Dairy Habit Boost Parkinson's Risk?
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

Diabetes Drug Shows Promise Against Parkinson's

HealthDay News
by -- Robert Preidt
Updated: Aug 4th 2017

new article illustration

FRIDAY, Aug. 4, 2017 (HealthDay News) -- The diabetes drug exenatide (Byetta) may do double duty as a treatment for Parkinson's disease, a new study suggests.

"This is a very promising finding, as the drug holds potential to affect the course of the disease itself, and not merely the symptoms," said senior study author Tom Foltynie, from University College London's Institute of Neurology.

"With existing treatments, we can relieve most of the symptoms [of Parkinson's] for some years, but the disease continues to worsen," he said in a university news release. "This is the strongest evidence we have so far that a drug could do more than provide symptom relief for Parkinson's disease."

Parkinson's is the second most common neurodegenerative disease worldwide, the researchers noted. The condition results in muscle stiffness, slowed movement, tremors, sleep disturbance and chronic fatigue.

In the study, 60 people with Parkinson's received either a weekly injection of exenatide or an inactive placebo for 48 weeks, along with their regular medications.

At the end of that period, those who took the diabetes drug scored four points higher on a 132-point scale of agility, speech and tremors than those who took the placebo. The difference was statistically significant, the study authors said.

The findings were published Aug. 3 in the The Lancet.

According to Brian Fiske, senior vice president of research programs at The Michael J. Fox Foundation for Parkinson's Research, "Using approved therapies for one condition to treat another, or drug repurposing, offers new avenues to speed Parkinson's therapeutic development." The foundation funded the study.

"The results from the exenatide studies justify continued testing, but clinicians and patients are urged not to add exenatide to their regimens until more is known about their safety and impact on Parkinson's," Fiske said.

Another Parkinson's expert agreed that more research is in order.

"While these are exciting findings, the observed benefit was small and only in one outcome-measure," said Dr. Martin Niethammer, a neurologist at Northwell Health's Neuroscience Institute, in Manhasset, N.Y.

"This might relate to the study being relatively small and of short duration, rather than lack of efficacy [effectiveness] of exenatide, and more study is certainly needed," he noted.

"This trial does provide an excellent rationale for larger and longer trials, and it remains to be seen if exenatide, and drugs like it, truly have a disease-modifying effect or merely improve the symptoms of Parkinson's disease," Niethammer said.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on Parkinson's disease.